Aspira Pathlab & Diagnostics Ltd.

View in App
42.60 -0.30 ▼-0.7%

30 November 2023, 12:49:00 PM
Volume: 5

Company Profile

View details >>
Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.aspiradiagnostics.com
Market Cap 43.85 Cr.
Enterprise Value(EV) 43.78 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -1.21 Trailing Twelve Months Ending 2023-09
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-09
Industry PE 61.75 Trailing Twelve Months Ending 2023-09
Book Value / Share 11.00 Trailing Twelve Months Ending 2023-09
Price to Book Value 3.87 Calculated using Price: 42.60
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.03 Cr. 10,293,000 Shares
FaceValue 10
About Aspira Pathlab & Diagnostics Ltd.
The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.

Aspira Pathlab & Diagnostics Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Aspira Pathlab & Diagnostics Ltd. Performance

View details >>
1 Day
-0.70%
1 Week
+12.11%
1 Month
+17.81%
3 Month
+3.00%
6 Month
+32.79%
1 Year
+0.59%
2 Year
-49.79%
5 Year
+127.81%
10 Year

Aspira Pathlab & Diagnostics Ltd. Fundamental Ratios

View details >>
9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 1.10 0.76 -57.04 -178.61 -187.57 -94.32 22.80 42.26 -0.69
Return on Capital Employed (%) 3.95 1.78 -25.35 -38.38 -34.50 -26.30 21.52 41.63 2.40
Return on Assets (%) 1.05 0.54 -25.76 -40.76 -37.93 -29.11 10.58 29.82 -0.50

Aspira Pathlab & Diagnostics Ltd. Balance Sheet

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 4 4 6 0 5 4 8 13 13 11
Non Curr. Liab. 3 11 5 5 1 4 3 3
Curr. Liab. 0 3 6 2 4 5 2 2 2 2
Minority Int.
Equity & Liab. 4 6 15 13 15 14 12 18 17 16
Non Curr. Assets 1 11 11 13 11 8 11 11 11
Curr. Assets 4 6 4 2 2 3 4 7 6 5
Misc. Exp. not W/O
Total Assets 4 6 15 13 15 14 12 18 17 16

Aspira Pathlab & Diagnostics Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09 Rs. Cr. TTM
Net Sales 1 4 8 8 15 20 14 14
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 1 5 8 9 15 20 15 14
Total Expenditure 0 0 -3 -8 -11 -10 -12 -13 -13 -13
PBIDT 0 0 -2 -4 -3 -2 4 6 2 1
Interest 0 0 0 -1 -1 -1 -1 0 0 0
Depreciation 0 -1 -1 -2 -1 -2 -2 -2
Taxation 0 0 0
Exceptional Items
PAT 0 0 -3 -6 -5 -4 1 4 0 -1
Adjusted EPS 0 0 -5 -11 -6 -5 1 4 0 -1

Aspira Pathlab & Diagnostics Ltd. Cash Flow

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 0 -1 -5 -3 -2 6 2 0
Cash Fr. Inv. 0 0 0 -10 -1 -2 0 0 -1 0
Cash Fr. Finan. 3 3 9 7 3 1 -2 -1 -1
Net Change 0 3 2 -3 1 -2 0 3 0 -1
Cash & Cash Eqvt 0 3 5 3 0 -2 -2 1 1 1

Aspira Pathlab & Diagnostics Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%)
Promoter 36.25 36.25 36.25 36.19 34.55 19.48 19.47 19.37 18.90
Public 63.75 63.75 63.75 63.81 65.45 80.52 80.53 80.63 81.10
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Aspira Pathlab & Diagnostics Ltd. Announcements

View details >>
Mon, 13 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement for Unaudited Financial Results for the quarter and the half year ended September 30 2023
Sat, 11 Nov 2023
Board Meeting Outcome for Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Financial Results for the Second Quarter and Half Year Ended 30th September 2023 duly approved by the Audit Committee and Board Meeting in its meeting held on November 11 2023
Sat, 28 Oct 2023
Board Meeting Intimation for The Board Meeting To Be Held On Saturday November 11 2023 To Consider And Approve Unaudited Financial Results For The Quarter And Half Year Ended September 30 2023
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2023 inter alia to consider and approve Standalone Unaudited Financial Results for the quarter and half year ended as on September 30 2023

Aspira Pathlab & Diagnostics Ltd. Technical Scans

View details >>
Wed, 29 Nov 2023
Opening at High Opening at High
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Above Last Week High Close Above Last Week High
Close Above Last Month High Close Above Last Month High
Opening at High for 2 Days Opening at High for 2 Days

Aspira Pathlab & Diagnostics Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 288,124.14 1,211.00 +0.7%
Divi's Laboratories Ltd. 98,985.27 3,788.00 +1.6%
Cipla Ltd. 97,035.44 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. 95,335.50 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. 77,919.78 5,495.20 +1.4%
Mankind Pharma Ltd. 76,041.70 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. 70,779.09 2,124.30 +1.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 33.70 1,211.00 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-09 74.33 3,788.00 +1.6%
Cipla Ltd. Consolidated 2023-09 28.10 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 18.73 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 111.72 5,495.20 +1.4%
Mankind Pharma Ltd. Consolidated 2023-03 59.32 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 53.06 2,124.30 +1.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 4.82 1,211.00 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-09 7.81 3,788.00 +1.6%
Cipla Ltd. Consolidated 2023-09 3.91 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 3.74 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 11.99 5,495.20 +1.4%
Mankind Pharma Ltd. Consolidated 2023-03 9.02 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 10.55 2,124.30 +1.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,211.00 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,788.00 +1.6%
Cipla Ltd. Consolidated 2023-03 0.02 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 5,495.20 +1.4%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,124.30 +1.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,211.00 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,788.00 +1.6%
Cipla Ltd. Consolidated 2023-03 12.85 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,495.20 +1.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,124.30 +1.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,211.00 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,788.00 +1.6%
Cipla Ltd. Consolidated 2023-03 12.85 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,495.20 +1.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,124.30 +1.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,211.00 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,788.00 +1.6%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 5,495.20 +1.4%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,124.30 +1.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,211.00 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,788.00 +1.6%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,199.45 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,750.40 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 5,495.20 +1.4%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 1,890.30 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,124.30 +1.6%

Aspira Pathlab & Diagnostics Ltd. FAQ's

What is Aspira Pathlab&Diagn share price?
Can I buy Aspira Pathlab&Diagn shares now?
What is the Market Cap of Aspira Pathlab&Diagn?
What are the key metrics to analyse Aspira Pathlab&Diagn?
What is the 52 Week High and Low of Aspira Pathlab&Diagn?
What is the trend of Aspira Pathlab&Diagn share price?